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Background and purpose: Mutations in the low-density lipoprotein receptor (LDLR) gene cause familial
hypercholesterolaemia in humans and deletion of the LDLR induces lesion development in mice fed a high-fat diet. LDLR
expression is predominantly regulated by sterol regulatory element-binding protein 2 (SREBP2). Fenofibrate, a peroxisome
proliferator-activated receptor a (PPARa) ligand, belongs to a drug class used to treat dyslipidaemic patients. We have
investigated the effects of fenofibrate on hepatic LDLR expression.
Experimental approach: The effects of fenofibrate on hepatic LDLR expression (mRNA and protein) and function were
evaluated by both in vitro (with AML12 cells) and in vivo experiments in mice.
Key results: Fenofibrate increased LDLR expression and LDL binding in a mouse hepatoma cell line, AML12 cells. Fenofibrate
restored sterol-inhibited hepatocyte LDLR expression. Mechanistic studies demonstrated that induction of LDLR expression by
fenofibrate was dependent on PPARa and sterol regulatory elements (SRE). Specifically, fenofibrate induced LDLR expression by
increasing maturation of SREBP2 and phosphorylation of protein kinase B (Akt) but had no effect on SREBP cleavage-activating
protein. In vivo, a high-fat diet suppressed LDLR expression in mouse liver while elevating total and LDL cholesterol levels in
plasma. However, fenofibrate restored LDLR expression inhibited by high-fat diets in the liver and reduced LDL cholesterol
levels in plasma.
Conclusions and implications: Our data suggest that fenofibrate increased hepatic LDLR expression in mice by a mechanism
involving Akt phosphorylation and LDLR gene transcription mediated by SREBP2.
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Introduction
Expression of the low-density lipoprotein receptor (LDLR) is
regulated at the transcriptional and/or translational levels.
Cholesterol and its derivatives inhibit LDLR expression that
results in a reduction of cellular cholesterol uptake. In this
feedback regulatory pathway, the sterol regulatory element-
binding protein 2 (SREBP2) has a crucial function (Goldstein
et al., 2006). SREBPs are transcription factors belonging to the
basic helix–loop–helix–leucine zipper (bHLH-Zip) family. They
consist of three isoforms, namely SREBP-1a, SREBP-1c and
SREBP2 (Goldstein et al., 2006). SREBP1 is responsible for fatty
acid synthesis and metabolism, whereas SREBP2 controls
expression of LDLR and 3-hydroxy-3-methylglutaryl coenzyme
A (HMG-CoA) reductase, the rate-limiting enzyme for choles-
terol synthesis (Brown and Goldstein, 1997; Shimano, 2001).
SREBP 1 and 2 are synthesized in the rough endoplasmic
reticulum (ER) as precursor proteins and bind to the SREBP
cleavage-activating protein (SCAP). In sterol-depleted cells,
SCAP chaperones SREBP from the ER to the Golgi where the
SREBP is cleaved by two Golgi residing proteases, site-1 protease
(S1P) and site-2 protease (S2P). The released bHLH-Zip domain
of SREBP or nuclear form of SREBP (nSREBP) translocates into
the nucleus, and then binds to the sterol regulatory element
(SRE) in the promoter region of target genes, including the
BJPOpen  
Received 24 April 2008; revised 11 June 2008; accepted 21 July 2008;
published online 18 August 2008
Correspondence: Dr J Han, Department of Pathology, Center of Vascular
Biology, Weill Cornell Medical College, 1300 York Avenue, E-012, New York,
NY 10065, USA.
E-mail: Jhan@med.cornell.edu
4These authors contributed equally to this work.
British Journal of Pharmacology (2008) 155, 596–605
& 2008 Macmillan Publishers Limited All rights reserved 0007–1188/08 $32.00
www.brjpharmacol.orgLDLR, and activates transcription. In contrast, cholesterol
binds to the sterol-sensing domain of SCAP in lipid-loaded
cells and causes a change in SCAP conformation, allowing
SCAP to bind to a pair of ER membrane proteins, Insig1 and
Insig2. The formation of the SREBP/SCAP/Insig complex
prevents the processing of SREBP and inhibits the expression
of SREBP target genes (Nohturfft et al., 1999; Yang et al., 2002;
Adams et al., 2003; Radhakrishnan et al., 2004).
Peroxisome proliferator-activated receptors (PPARs) in-
cluding PPARa,P P A R b/d and PPARg are ligand-activated
transcription factors that regulate lipid metabolism, glucose
homoeostasis, inflammation and the development of
adipocyte differentiation (Gilde et al., 2006). Both PPARa
and PPARg ligands are anti-atherogenic in mouse models
of atherosclerosis (Li et al., 2000; Duez et al., 2002). They
have been shown to decrease cardiovascular end points in
clinical trials (Helsinki Heart Study, Veterans Affairs High-
Density Lipoprotein Cholesterol Intervention Trial (VA-HIT),
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) and Prospective Pioglitazone Clinical Trial in
Macrovascular Events (PROactive)) (Dormandy et al., 2005;
Keech et al., 2005; Backes et al., 2007). Fibric acid derivatives
(such as, fenofibrate) are PPARa ligands used in the
treatment of dyslipidaemia in patients with diabetes. They
reduce plasma triglyceride levels, increase high-density
lipoprotein (HDL) cholesterol levels and shift the distribu-
tion of LDL subfractions towards larger, less atherogenic
particles (Vu-Dac et al., 1995; Berthou et al., 1996).
Increased hepatic LDLR expression is one of the most
effective means to lower plasma cholesterol levels (Bays and
Stein, 2003). In some clinical studies, PPARa agonists have
been shown to reduce LDL cholesterol levels, particularly
in the presence of hypertriglyceridaemia with unrevealed
mechanisms. In patients with hypertriglyceridaemia, LDL
cholesterol may increase, but this is due to an increase in
particle size but not in particle number (Davidson et al., 2006).
In this study, we hypothesized that fenofibrate, a PPARa
ligand, might reduce plasma LDL cholesterol levels through
increased hepatic LDLR expression. We provide studies that
show for the first time that fenofibrate increased LDLR
expression and uptake of LDL by hepatocytes in a manner
dependent on the activation of PPARa. Our in vivo studies
further show that administration of fenofibrate in mouse
induced liver LDLR expression and reduced plasma LDL
cholesterol levels, and that this process occurred though the
activation of SREBP2 and phosphorylation of Akt.
Methods
Cell culture
The AML12 murine hepatocyte cell line (ATCC CRL-2254)
(Wu et al., 1994) was purchased from ATCC (Manassas, VA,
USA) and cultured in complete growth medium prepared as
follows: 1:1 of Dulbecco’s modified Eagle’s medium (DMEM)
and Ham’s F12 medium with 5mgmL
 1 insulin, 5mgmL
 1
transferrin, 5ngmL
 1 selenium, 40ngmL
 1 dexamethasone,
10% foetal bovine serum (FBS) and 50mgmL
 1 penicillin/
streptomycin. Cells were switched to serum-free medium
and received treatments when confluent.
Human kidney 293 cell line was also purchased from
ATCC and cultured in complete DMEM medium (10% FBS
and 50mgmL
 1 penicillin/streptomycin).
Animals
All animal procedures were in strict compliance with NIH
guidelines. C57BL wild-type mice (at the age of 10 weeks and
about 25g) were purchased from The Jackson Laboratory
(Bar Harbor, ME, USA) and maintained in fully accredited
facilities (AAALAC) at Weill Medical College of Cornell
University. Mice were divided into three groups at the
time of the experiments. Group 1 was left on normal
chow, whereas the other two groups were initially fed with
a high-fat diet for 2 weeks. They were then further divided
as follows: a high-fat diet alone or a high-fat diet plus
fenofibrate (50mg per 100g food). We assumed that the
intake of fenofibrate by mice was about 50mgday
 1 per kg
body weight, based on the following calculation: a 25g
mouse eats 2.5g food a day, thus the intake of fenofibrate is
2.5 50/100/0.025¼50. After 10 days of treatment with
fenofibrate, mice were killed and blood or liver was
individually collected. Plasma was prepared by centrifuging
blood samples for 5min at 400 g and was kept at –201C for
assay of total, LDL and HDL cholesterol levels. The liver was
used to extract cellular total RNA.
Isolation of total RNA and northern blot analysis of LDLR,
HMG-CoA reductase and SCAP mRNA expression
Total cellular RNA was extracted from cells or liver and used
to determine the levels of mouse LDLR, HMGCR (HMG-CoA
reductase), SCAP and GAPDH (glyceraldehyde 3-phosphate
dehydrogenase) mRNA by northern blot analysis as des-
cribed (Han et al., 2004). Probes were generated by reverse
transcription-PCR based on the published sequence. The
sequences of primers are LDLR-f: GACTGCAAGGACATGA
GCGA (781-801); LDLR-r: CGGTTGGTGAAGAGCAGATA (1221-
1201); HMGCR-f: CGTTGGCTGGAGACGGCA (121-138),
HMGCR-r, CACTGACATGCAGCCGAA (798-781); SCAP-f,
TTCTGGCAGTCGATGTGTTC (573–592); and SCAP-r, GACCA
CCAGGTATGGGAAGA (1309-1280).
Western blot analysis of LDLR, SREBP2, PPARa, total Akt and
phospho-Akt protein expression
After treatment, cells were washed twice with cold phos-
phate-buffered saline, then scraped and lysed in ice-cold lysis
buffer (50mM Tris, pH 7.5, 150mM NaCl, 1% Triton X-100,
1% sodium deoxycholate, 1mM phenylmethanesulphonyl
fluoride, 50mM sodium fluoride, 1mM sodium orthovana-
date, 50mgmL
 1 aprotinin and 50mgmL
 1 leupeptin). If the
lysis buffer was used to extract cellular proteins for total Akt
and phospho-Akt analysis, 1mM b-glycerol phosphate and
2.5mM sodium pyrophosphate were added. Cellular lysate
was centrifuged at 400 g for 15min at 41C, and superna-
tants were transferred into a new test tube. After measuring
the protein content, lysates were loaded and separated on a
12% SDS-polyacrylamide gel electrophoresis and trans-
ferred onto nylon-enhanced nitrocellulose membrane. The
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20 (TBS-T) containing 5% fat-free dry milk for 1h, and then
incubated with primary antibody overnight at 41C followed
by washing for 3 10min with TBS-T buffer. The blot was
re-blocked with TBS/T containing 5% milk, followed by
incubation with horseradish peroxidase-conjugated second-
ary antibody for 1h at room temperature. After washing
3 10min with TBS-T, the membrane was incubated for
1min in a mixture of equal volumes of western blot
chemiluminescence reagents 1 and 2, and then exposed to
film before development.
Isolation of LDL and analysis of LDL binding to hepatocytes
LDL (1.019–1.063gmL
 1) was isolated from normal human
plasma by sequential ultracentrifugation. To conduct the
binding of LDL to hepatocytes, LDL was fluorescein
conjugated with a reactive succinimidyl-ester of carboxyl-
fluorescein by using a labelling kit purchased from Princeton
Separations (Adelphia, NJ, USA). Hepatocytes were cultured
in a four-well slide chamber. After treatment, cells were
washed twice with phosphate-buffered saline and then
incubated with 30mgmL
 1 of labelled LDL in serum-free
medium for 2h at 371C. After washing twice with
phosphate-buffered saline and covering with Vectashield
mounting medium (Vector Laboratories Inc., Burlingame,
CA, USA), cells were observed with a fluorescent microscope
and photographed.
Construction and determination of LDLR promoter activity
A mouse LDLR promoter including the SRE (pLDLR, from
 331 to þ49, SRE in LDLR (ATCACCCCAT) locates from
 213 to  204) was generated by PCR with primers, pLDLR-f,
50-CGGCCAAGCTTGCTGTGGGAGGAATTTGAGGA-30 and
pLDLR-r, 50-GGCCACCATGGAAGGAGCAGGGCGATGAC-30,
and genomic DNA isolated from mouse liver. The primers
contained restriction sites for HindIII (50 primer) and NcoI
(30 primer), respectively. After the sequence was confirmed,
the PCR product was digested by enzymes and then sub-
cloned into pGL4.10 luciferase reporter vector (Promega,
Madison, WI, USA) to generate the LDLR promoter (pLDLR-
Luc) and amplified. The LDLR promoter with a mutation in
SRE (pLDLR-SREmu-Luc) was generated by using a Quik-
Change II Site-Directed Mutagenesis Kit (Stratagene, La Jolla,
CA, USA), DNA of pLDLR-Luc, and the following primers:
pLDLR SREmu-f, 50-gaagatttttgaaaATCACGGCATtgcagactcct
ccccg-30 (CC in SRE motif (in caps) was replaced by GG
(underlined)); pLDLR SREmu-r, 50-ggggaggagtctgcaATGCCG
TGATtttcaaaaatcttc-30.
About 90% confluent 293 cells in 24-well plates were
transfected with 1mg per well of pLDLR-Luc or pLDLR-
SREmu-Luc plus Renilla luciferase reporter (RLuc, for internal
control) by using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). After transfection for 8h, the cells were treated
overnight. After washing with phosphate-buffered saline,
the cells were lysed and the activity of pLDLR-Luc or
pLDLR-SREmu-Luc and RLuc in cellular lysate was deter-
mined by using a Dual-Luciferase Reporter Assay System from
Promega.
Data analysis
All experiments were repeated three times except as
indicated, and representative results are presented. Data
generated from the cholesterol assays and the activity assays
of LDLR promoters were expressed as mean±s.e.mean and
analysed by paired t-test.
Materials
Fenofibrate, GW7647, GW9662, LY294002 and LY303511
were purchased from CalBiochemistry (San Diego, CA, USA)
and prepared in dimethyl sulphoxide. Control and PPARa
siRNAs, siRNA transfection medium and reagents, and
polyclonal anti-PPARa antibody were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, CA, USA). High-fat diet
(21% fat and 0.2% cholesterol) was purchased from Harlan
Teklad (Madison, WI, USA). Rabbit anti-mouse LDLR anti-
body was purchased from R&D Systems (Minneapolis, MN,
USA). Rabbit anti-mouse total Akt and phospho-Akt (Ser473)
were obtained from Cell Signaling Technology (Beverly, MA,
USA). Rabbit anti-aP2 serum was generated by immunization
with murine aP2 peptide of DGKSTTIKRKRDGDKLV (Sun
et al., 2003). Rabbit-anti mouse-SREBP2-specific polyclonal
antibody was a gift of Dr Joseph Goldstein from The
University of Southwestern Medical Center. Total, LDL and
HDL cholesterol assay kits were purchased from Wako
Chemicals (Richmond, VA, USA). All other reagents were
obtained from Sigma-Aldrich Chemicals (St Louis, MO, USA)
except as indicated.
Results
Fenofibrate induces LDLR expression in hepatocytes
in a PPARa-dependent manner
To study the effects of fenofibrate on hepatic LDLR expres-
sion, a mouse hepatocyte cell line, AML12 cells, was treated
overnight with different concentrations of fenofibrate in
serum-free medium. Changes in LDLR mRNA were assessed
by northern blot analysis (Figure 1a). Fenofibrate induced
hepatocyte LDLR mRNA expression in a concentration-
dependent manner. Maximal induction was observed with
25mM of fenofibrate.
To determine whether the induction of LDLR mRNA by
fenofibrate was associated with the induction of LDLR
protein, total cellular protein was extracted from cells after
treatment with fenofibrate and used to determine LDLR
protein expression by western blot analysis. Consistent with
the changes in LDLR mRNA expression, LDLR protein was
increased by fenofibrate in a concentration-dependent
manner, with maximal induction of LDLR protein expres-
sion at a concentration of 10mM (Figure 1a).
The temporal effects of fenofibrate on LDLR expression
were assessed by time course studies. Cells were treated with
fenofibrate (10mM) for up to 24h and changes in LDLR
protein were analysed by western blot. Induction of LDLR
protein expression by fenofibrate was first observed at 6h,
and maximal expression was observed at 12h (Figure 1b).
To correlate the induction of LDLR expression in response
to fenofibrate with the LDLR function, LDL binding to
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cytes was significantly enhanced by fenofibrate in a
concentration-dependent manner (Figure 1c).
To study if the induction of hepatic LDLR expression by
fenofibrate was dependent on the activation of PPARa,w e
initially treated hepatocytes with another PPARa agonist,
GW7647 (Muoio et al., 2002), and determined its effects on
LDLR expression. Similar to fenofibrate, GW7647 induced
LDLR expression in a dose-dependent manner (Figure 2a). In
contrast, a PPARa antagonist, GW9662 alone (Brown et al.,
2001; Leesnitzer et al., 2002), moderately inhibited hepatic
LDLR expression. It also blocked fenofibrate-induced hepatic
LDLR expression (Figure 2b). Induction of adipose fatty
acid-binding protein (A-FABP or aP2) in the liver is also
dependent on PPARa activity (Motojima, 2000). Thus,
increased aP2 expression in hepatocytes in response to
fenofibrate will indicate the activation of PPARa. Indeed,
we observed a strong induction of aP2 expression in
hepatocytes by fenofibrate (Figure 2c). To further confirm if
the induction of hepatic LDLR expression by fenofibrate is
PPARa-dependent, we used siRNA to reduce PPARa expres-
sion. Results in Figure 2d indicate that PPARa siRNA
significantly reduced PPARa levels, whereas a control siRNA
had no effect on PPARa.P P A R a siRNA alone decreased the
expression of hepatocyte LDLR. More importantly, as PPARa
siRNA did not completely inhibit PPARa expression, as
compared with PPARa siRNA alone, the co-treatment of
fenofibrate and PPARa siRNA induced LDLR expression
(Figure 2d).
To examine the physiological relevance of fenofibrate-
induced hepatic LDLR expression, wild-type mice were
fed with normal chow or a high-fat diet or a high-fat
diet containing fenofibrate. The effects of fenofibrate
on LDLR mRNA expression in the liver, and the levels
of total, LDL and HDL cholesterol in plasma were deter-
mined. Compared with normal chow, a high-fat diet
increased total and LDL cholesterol levels (163 and 139%
of control group, respectively, Table 1). However, fenofibrate
abolished the elevation of circulating LDL cholesterol.
The increased total cholesterol in mice given fenofibrate
was partially due to increased HDL cholesterol (Table 1). To
study if the reduction of LDL cholesterol in response
to fenofibrate was due to the increased LDLR-mediated
LDL clearance, the expression of liver LDLR mRNA in mice
was assessed by northern blot analysis. As expected, a high-
fat diet inhibited LDLR mRNA expression in mouse liver
(43% of group on normal chow, Figure 3). In contrast, the
addition of fenofibrate in the high-fat diet abolished the
decline of LDLR mRNA levels (96% of group on normal
chow, Figure 3).
Figure 1 Fenofibrate induces hepatic LDLR expression and function. (a) Fenofibrate induces LDLR mRNA and protein expression: confluent
mouse hepatocytes (AML12 cells) in serum-free medium were treated with fenofibrate at the indicated concentrations overnight. Total cellular
RNA or proteins were extracted and used to determine the levels of hepatic LDLR mRNA or protein by northern or western blot analysis as
described in the Methods section. (b) Fenofibrate induces LDLR protein expression and time course: hepatocytes in serum-free medium were
treated with fenofibrate (10mM) for indicated times. Cellular proteins were extracted and used to determine the levels of LDLR protein by
western blot analysis. (c) Fenofibrate induces the binding of LDL to hepatocytes: hepatocytes were treated overnight with fenofibrate at the
indicated concentrations. LDL binding assays were performed as described in the Methods section. LDLR, low-density lipoprotein receptor.
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LDLR expression is feedback inhibited by cellular sterol
levels. Thus, cholesterol or lipid ‘loading’ will inhibit LDLR
expression. This mechanism not only prevents cells from
uncontrolled accumulation of lipids but also reduces the
clearance of excess LDL cholesterol from the circulation by
the liver during hyperlipidaemia. To determine whether
fenofibrate would restore LDLR expression suppressed by
lipids, cells were treated with LDL or 25-hydroxycholesterol
or lipid plus fenofibrate. LDL and 25-hydroxycholesterol
inhibited LDLR protein expression in AML12 hepatocytes
(Figure 4). This inhibitory effect was abolished in the
presence of fenofibrate, suggesting that fenofibrate restores
the LDLR expression inhibited by sterols (Figure 4).
Table 1 Effect of fenofibrate on mouse plasma cholesterol levels (mgL
 1)
Treatment Total C LDL C HDL C
Control (normal chow) 782±90 196±17 465±50
High-fat diet 1277±38* 271±24* 749±46*
High-fat dietþfenofibrate 1508±48*
,# 211±13
# 997±45*
,#
Abbreviations: C, cholesterol; HDL, high-density lipoprotein; LDL, low-density
lipoprotein.
Mice at the age of 10 weeks were divided into three groups. Control group
was fed with normal chow. Other two groups were fed a high-fat diet for 2
weeks followed by drug treatment as described in the Methods section. At the
end of experiments, plasma and liver were collected from each mouse. Total,
LDL and HDL cholesterol levels were determined.
*Significantly different from control group at Po0.05;
#significantly different
from group of high-fat diet alone at Po0.05, by Student’s t-test (n¼5).
Figure 3 Fenofibrate induces LDLR expression in mouse liver. (a)
Mice were treated as described in Table 1. Total RNA was extracted
from the mouse liver, and the expression of LDLR mRNA was
determined by northern blot analysis. The same blot was
re-hybridized with
32P-labeled GAPDH probe for internal control.
(b) Summary of northern blot results indicating the significant
difference (Po0.05, n¼3) between groups of normal chow and
high-fat diet, or groups of high-fat diet and high-fat dietþfeno-
fibrate, but not between groups of normal chow and high-fat
dietþfenofibrate. GAPDH, glyceraldehyde 3-phosphate dehydro-
genase; LDLR, low-density lipoprotein receptor.
Figure 2 Induction of hepatocyte LDLR expression by fenofibrate is
PPARa-dependent. (a) Induction of hepatocyte LDLR expression by
GW7647, another PPARa ligand: confluent hepatocytes were treated
with another PPARa agonist, GW7647 at the indicated concentra-
tions overnight. The expression of LDLR protein was determined by
western blot analysis. (b) PPARa antagonist, GW9662, blocks
fenofibrate-induced LDLR expression: confluent hepatocytes were
treated with GW9662 or fenofibrate alone or co-treated with
GW9662 and fenofibrate at the indicated concentrations overnight.
Changes in LDLR protein was assessed by western blot analysis. (c)
Induction of hepatocyte aP2 expression by fenofibrate: confluent
hepatocytes were treated with fenofibrate at the indicated concen-
trations overnight. Expression of aP2 was determined by western
blot analysis. (d) PPARa siRNA inhibits LDLR expression: confluent
hepatic cells in six-well plates were transfected with control siRNA or
PPARa siRNA for 6h followed by treatment with fenofibrate at
the indicated concentrations overnight. Expression of LDLR and
PPARa proteins were determined by western blot analysis. LDLR,
low-density lipoprotein receptor; PPARa, peroxisome proliferator-
activated receptor a.
Figure 4 Fenofibrate restores sterol-inhibited LDLR expression.
Hepatocytes were treated with fenofibrate (10mM) in the presence
or absence of LDL (100mgmL
 1) or 25-hydroxycholesterol (25-OH-
Chol, 10mM) overnight. Expression of LDLR protein was determined
by western blot analysis. LDLR, low-density lipoprotein receptor.
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activation of SREBP2 and Akt phosphorylation
LDLR expression is primarily regulated by the activity of
SREBP2, which is dependent on cellular sterol levels.
Fenofibrate restored sterol-suppressed LDLR expression,
suggesting that fenofibrate may modulate the SREBP2
pathway to activate hepatic LDLR expression. Initially, we
determined whether the induction of LDLR expression
by fenofibrate was SRE-dependent. The kidney cell line,
293 cells, was transfected with LDLR promoter-luciferase
constructs, including normal SRE or mutant SRE, followed
by treatment with fenofibrate or 25-hydroxycholesterol
or pitavastatin, a HMG-CoA reductase inhibitor. The activity
of the promoter containing the normal SRE sequence
was increased by pitavastatin (47%) and decreased by
25-hydroxycholesterol (42%), as expected. Fenofibrate
treatment significantly increased the activity of the LDLR
promoter containing normal SRE (42-fold) (Figure 5).
Mutation in the SRE reduced promoter activity and disabled
the regulation of promoter activity by pitavastatin and 25-
hydroxycholesterol. Fenofibrate did not influence the acti-
vity of the SRE mutant LDLR promoter, also suggesting an
essential role of SRE in the regulation of LDLR transcription
in response to fenofibrate.
SRE-dependent induction of LDLR promoter activity by
fenofibrate indicated that fenofibrate may activate SREBP2.
Thus, expression and maturation of SREBP2 in response to
fenofibrate was determined by western blot analysis. Results
shown in Figure 6a demonstrate that fenofibrate did not
induce SREBP2 expression. However, fenofibrate increased
the amount of mature SREBP2 and decreased SREBP2
precursor, suggesting that fenofibrate enhanced the proteo-
lysis of SREBP2. To further confirm the activation of SREBP2
by fenofibrate, we evaluated the expression of HMG-CoA
reductase mRNA, another target gene regulated by SREBP2
activity. HMG-CoA reductase mRNA was also increased in
response to fenofibrate (Figure 6b).
Levels of SCAP or translocation of the SCAP–SREBP2
complex from the ER to the Golgi affect the maturation of
SREBP2. To test if fenofibrate was able to induce SCAP
expression, its effect on SCAP mRNA expression was assessed
by northern blot analysis. Results shown in Figure 6c
indicate that SCAP expression was unaffected by fenofibrate
treatment.
The activity of the protein kinase Akt influences the
SREBP2 processing and expression of the LDLR (Du et al.,
2006). To study if the activation of SREBP2 by fenofibrate
Figure 5 Induction of hepatic LDLR expression by fenofibrate is
sterol regulatory elements (SRE)-dependent. Confluent 293 kidney
cells were transfected with plasmid DNA of normal LDLR promoter
(pLDLR-luc) or SRE mutant LDLR promoter (pLDLR-SREmu-Luc)
plus Renilla luciferase reporter (RLuc) followed by treatment with
fenofibrate (10mM) or 25-hydroxycholesterol (25-OH-Chol, 10mM)
or pitavastatin (10mM) overnight in serum-free medium. Promoter
activity was analysed as described in the Methods section. The
relative luciferase activity of the LDLR promoter was calculated based
on the activity of co-transfected Rluc. The activity of normal LDLR
promoter without treatment was defined as 100%. *Significantly
different from normal LDLR promoter without treatment at Po0.05
by Student’s t-test (n¼4). LDLR, low-density lipoprotein receptor.
Figure 6 Fenofibrate induces maturation of sterol regulatory
element-binding protein 2 (SREBP2) and expression of 3-hydroxy-
3-methylglutaryl coenzyme A (HMG-CoA) reductase, but has no
effect on the expression of SREBP cleavage-activating protein
(SCAP). (a) Hepatocytes were treated with fenofibrate at the
indicated concentrations overnight. Total cellular proteins were
extracted and used to determine the levels of precursor of SREBP2
(P) and mature SREBP2 (N) by western blot analysis. Hepatocytes in
serum-free medium were treated with fenofibrate at the indicated
concentrations overnight. Total cellular RNA was collected and used
to determine the expression of HMG-CoA reductase mRNA (b) and
SCAP mRNA (c), respectively, by northern blot analysis.
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phosphorylated Akt in response to fenofibrate treatment was
assessed by western blot analysis. Figure 7a demonstrates
that fenofibrate increased phosphorylated Akt but had no
effect on total Akt expression. Furthermore, LY294002, a
phosphoinositide 3-kinase (PI3K, the primary activator of
Akt phosphorylation) inhibitor (Song et al., 2005), blocked
the induction of Akt phosphorylation by fenofibrate
(Figure 7b).
To correlate changes in Akt activity with expression of the
LDLR in response to fenofibrate, we treated hepatacytes with
a PI3K inhibitor, LY294002, or a negative control for the PI3K
inhibitor, LY303511. Results in Figure 8a demonstrate that
the PI3K inhibitor reduced LDLR expression. The negative
control for the PI3K inhibitor had little effect on LDLR
expression. We then evaluated whether the PI3K inhibitor
was able to block fenofibrate-induced LDLR expression.
Consistent with changes in phospho-Akt, the induction
of LDLR expression by fenofibrate was blocked by a PI3K
inhibitor, LY294002 (Figures 8b), whereas the negative
control for PI3K inhibitor (LY303511) slightly enhanced
fenofibrate-induced LDLR expression (Figure 8c).
Discussion
Clearance of excess plasma LDL cholesterol occurs through
binding of LDL to the hepatic LDLR. Thus, increased LDLR
expression in the liver can reduce plasma LDL cholesterol.
Statins, the most commonly used therapeutic agents to
lower plasma LDL cholesterol, act to increase liver LDLR
expression by inhibiting cholesterol synthesis in hepato-
cytes. Herein, we demonstrate for the first time that
fenofibrate induces the expression of LDLR mRNA and
protein in a mouse hepatocyte cell line (AML12 cells) and
that the induction of LDLR expression enhances LDL
uptake. The induction of hepatic LDLR expression is not a
fenofibrate-specific effect but rather a PPARa ligand-depen-
dent effect (that is, dependent on the activation of PPARa).
Administration of fenofibrate induced expression of the
LDLR in mouse liver reducing the plasma levels of LDL
cholesterol. The increase in hepatic LDLR expression by
fenofibrate is sustainable and dependent on the SRE and the
activity of SREBP2, the primary transcriptional regulator of
LDLR expression. Moreover, our data show that increased
phosphorylation of Akt results in enhanced SREBP2
processing.
Induction of hepatic LDLR expression by fenofibrate was
SRE-dependent (Figure 5). Suppression of hepatic LDLR
expression by lipid treatment in vitro or by feeding mice a
high-fat diet is also dependent on the action of lipids on SRE
in the LDLR promoter (Brown and Goldstein, 1997). There-
fore, fenofibrate was able to restore sterol-inhibited hepatic
LDLR expression both in vitro and in vivo (Figures 3 and 4).
The SRE-dependent induction of hepatic LDLR expression by
fenofibrate suggests that the activity of SREBP2 is required.
Indeed, we observed that fenofibrate reduced the precursor
of SREBP2 but increased mature SREBP2, indicating that
the proteolysis of SREBP2 is enhanced. In addition, we
observed that fenofibrate increased the expression of
HMG-CoA reductase, another target gene of SREBP2. SCAP
is the molecule chaperoning SREBP2 from the ER to the
Golgi for SREBP2 processing. Interestingly, we observed that
the expression of SCAP was not altered in fenofibrate-treated
AML12 hepatocytes. Thus, the enhancement of ER-to-Golgi
transport of SCAP-SREBP2 most likely occurs by a different
mechanism.
Protein kinase B (Akt) is a critical regulator of cell
growth, proliferation and survival, and is itself activated by
PI3K (Song et al., 2005). Akt activity is also involved in
Figure 7 Fenofibrate increases Akt phosphorylation. Hepatocytes
were treated with fenofibrate at the indicated concentrations
overnight (a), or treated with fenofibrate (25mM) in the presence
or absence of LY294002 at the indicated concentrations overnight
(b). Cellular protein was extracted and used to determine total Akt
and phospho-Akt expressions by western blot analysis as described in
the Methods section.
Figure 8 Induction of hepatic low-density lipoprotein receptor
(LDLR) expression by fenofibrate is blocked by phosphoinositide 3-
kinase (PI3K) inhibition. (a) Confluent hepatocytes were treated with
the PI3K inhibitor (LY294002, LY29, 10mM) or the negative control
for the PI3K inhibitor (LY303511, LY30, 10mM) overnight. (b) Cells
were treated with fenofibrate (25mM) in the absence or presence of
PI3K inhibitor (LY294002) at the indicated concentrations overnight.
(c) Cells were treated with fenofibrate (25mM) in the absence or
presence of the negative control for the PI3K inhibitor (LY303511) at
the indicated concentrations overnight. Changes in LDLR protein
were assessed by western blot analysis.
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a specific inhibitor, LY294002, reduced SREBP2 processing
from its precursor to a mature form, thereby inhibiting the
expression of SREBP2 target genes, including the LDLR
(Du et al., 2006). Induction of SREBP maturation by sterol
depletion (for example, statin treatment) or by growth
factors (for example, epidermal growth factor, vascular
endothelial growth factor and insulin/insulin-like growth
factor-1) in different cell types can involve the activation
of Akt phosphorylation. This process can also be blocked
by PI3K-specific inhibitors (Borradaile et al., 2003; Zhou
et al., 2004; Porstmann et al., 2005). Inhibition of Akt
phosphorylation does not affect the binding of SCAP–Insig1,
but disrupts the transport of SCAP–SREBP2 from the ER to
the Golgi (Du et al., 2006). We interpret our studies to
suggest that Akt activity can play a critical role in
fenofibrate-induced hepatic LDLR expression, as fenofibrate
induced phoshorylation of Akt (Figure 7). Fenofibrate-
induced Akt activity, as well as hepatic LDLR expression,
was blocked by a PI3K inhibitor (Figures 7 and 8). Taken
together, our data demonstrate that fenofibrate can induce
hepatic LDLR expression by the activation of Akt and
consequently the maturation of SREBP2.
The effects of fenofibrate on serum total and LDL
cholesterol levels have been well examined in patients.
Although it did not greatly lower serum total and LDL
cholesterol levels (B10%) in patients with isolated hyper-
cholesterolaemia (LDL cholesterol41300mgL
 1 but trigly-
ceride levels are normal; Wierzbicki, 2006), fenofibrate
did significantly reduce serum total and LDL cholesterol
levels in patients with combined hypercholesterolaemia
(LDL cholesterol41300mgL
 1, triglycerides42000mgL
 1
and o10000mgL
 1), either as a monotherapy or a com-
bined therapy with a statin (Frost et al., 2001; Malik et al.,
2001; Athyros et al., 2002; Melenovsky et al., 2002; Sebestjen
et al., 2002; Vega et al., 2003; Wang et al., 2003; Derosa et al.,
2004; Winkler et al., 2004; Saklamaz et al., 2005; Grundy
et al., 2005; Iovine et al., 2006; Muhlestein et al., 2006;
Arca et al., 2007; Chatley et al., 2007). In these studies,
fenofibrate alone at a dose about 200mgday
 1 decreased
total cholesterol by 10–20% in combined hypercholesterol-
aemic patients after a few months (1–6) treatment. A similar
decrease was observed in serum LDL cholesterol. In a similar
period of treatment, statin therapy alone reduced total and
LDL cholesterol by a greater degree than fenofibrate (that is,
20–30% by cerivastatin and simvastatin, and 30–40% by
atorvastatin). Statins have little effect on HDL and only a
moderate effect on triglycerides. In contrast, fenofibrate can
increase HDL cholesterol and apolipoprotein AI/II levels, and
significantly decrease triglycerides. LDL consists of a hetero-
geneous group of particles. Among these particles, the small
or dense subfractions of LDL are believed the most
atherogenic. Statins decrease all subfractions of LDL to a
similar degree. In contrast, fenofibrate can decrease the small
or dense LDL more than the large or light LDL. Thus, statins
and fenofibrate have different impacts on the composition
of LDL in serum (Frost et al., 2001; Vega et al., 2003; Winkler
et al., 2004; Arca et al., 2007). For example, atorvastatin
decreased the dense LDL (dLDL) apoB in total LDL apoB by
5%, whereas fenofibrate reduced it by 36% (Winkler et al.,
2004). Simvastatin alone had little effect on LDL large/small
ratio (1.12 vs 0.94 by placebo). In combination with
fenofibrate, simvastatin increased this ratio to 2.37 (Vega
et al., 2003). More importantly, a combination therapy
of fenofibrate and a statin improved lipid profiles in
patients with combined hypercholesterolaemia in a syner-
gistic manner and lowered the dose of statin, potentially
reducing side effects (Athyros et al., 2002; Vega et al.,
2003; Derosa et al., 2004; Grundy et al., 2005; Muhlestein
et al., 2006). Fenofibrate also demonstrated several bene-
ficial effects on non-lipid biochemical risk factors, such
as C-reactive protein, Lp(a) and oxidation of LDL
(Athyros et al., 2002; Melenovsky et al., 2002; Wang et al.,
2003). Combined hypercholesterolaemia is very often
observed in type II diabetic patients. These studies suggest
the application of fenofibrate alone or in combination
with a statin in the treatment of lipid disorders in these
patients.
Effects of fibrates on cholesterol homoeostatsis were also
investigated in different animal models. Administration of
fenofibrate to rats reduced plasma cholesterol levels asso-
ciated with increased LDLR expression in the liver (Staels
et al., 1992). In contrast, fenofibrate induced expression of
cholesterol synthesis genes in mice (Le Jossic-Corcos et al.,
2004). Administration of fenofibrate to mice increased the
expression of HMG-CoA reductase and farnesyl pyro-
phosphate synthases, although the effect of fenofibrate
on plasma cholesterol levels and expression of LDLR in the
liver was not examined in this report. Induction of
HMG-CoA reductase and farnesyl pyrophosphate synthase
expression by fibrates was PPARa-dependent. Interestingly,
fenofibrate induced expression of SREBP1 but not SREBP2 at
mRNA levels in mouse liver (Le Jossic-Corcos et al., 2004).
Similarly, we observed that fenofibrate enhanced the proteo-
lysis, but not the expression of SREBP2 protein (Figure 6a).
Effect of fibrates on the expression of SREBP target genes
including LDLR may depend on the ligand and the duration
of treatment. WY14643 is a more selective PPARa ligand but
had less inductive effect than fenofibrate on HMG-CoA
reductase in mouse liver (Le Jossic-Corcos et al., 2004).
Fenofibrate induced LDLR expression in rat liver only after
3 days of administration, whereas WY14643 had no effect
on LDLR expression in mouse liver after the same duration
of treatment (Staels et al., 1992; Anderson et al., 2004).
Gemfibrozil induced LDLR expression, whereas clofibrate had
no effect on LDLR expression in rat liver. In contrast to the
results in clinical studies, administration of fibrates to rats
reduced apoA-I levels in plasma and suppressed expression of
apoA genes in the liver (Staels et al., 1992). In a recent report,
fenofibrate decreased plasma LDL cholesterol levels in
human apolipoprotein (apo) E2 knockin mice (Hennuyer
et al., 2005). Proprotein convertase subtilisin/kexin type 9
(PCSK9) is a natural inhibitor of LDLR expression. Recently,
fenofibrate has been reported to suppress the expression of
PCSK9 in human hepatocytes. This may be another potential
mechanism by which fenofibrate induces hepatic LDLR
expression (Kourimate et al., 2008).
In summary, our studies demonstrate for the first time that
fenofibrate increased hepatic LDLR expression in a PPARa-
dependent manner and reduced plasma LDL cholesterol
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lation was required for fenofibrate-induced hepatic LDLR
expression. Whether a similar PPARa-dependent mechanism
operates in humans remains to be determined.
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